---
schema_version: "secwatch.filing_event.v1"
accession: "0001161697-26-000243"
form_type: "8-K"
ticker: "KRMD"
cik: "0000704440"
company_name: "KORU Medical Systems, Inc."
filed_at: "2026-11-10T21:43:30+00:00"
generated_at: "2026-11-10T21:44:05.074294+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# KORU Medical Q3 revenue $11.6M, up 11%; net income $0.2M, second straight positive quarter

## Summary
- Net revenues $11.57M (+11.2% YoY); gross margin 65.2% vs 60.2%; gross profit $7.5M (+20.5%).
- Domestic core revenue $8.06M (+31.6%); international core $3.08M (-16.5%); pharma services $0.42M (-27.4%).
- Net income $0.2M ($0.00 diluted) vs prior-year net loss of $0.8M (-$0.02); adjusted EBITDA $1.3M vs $0.1M.
- FY2026 revenue guidance narrowed to $48.0-48.5M (17-18% growth) from $47.5-48.5M; gross margin raised to 63-64%.
- Signed two new sales and distribution agreements in Europe and Africa; year-end cash guidance raised to >$8.0M from >$7.5M.

## SEC filing metadata
- accession: 0001161697-26-000243
- form_type: 8-K
- ticker: KRMD
- cik: 0000704440
- company_name: KORU Medical Systems, Inc.
- filed_at: 2026-11-10T21:43:30+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/704440/000116169726000243/0001161697-26-000243-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/704440/000116169726000243/form_8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001161697-26-000243
- JSON: https://secwatch.observer/filing/0001161697-26-000243.json
- Plain text: https://secwatch.observer/filing/0001161697-26-000243.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.